|
TP1483L |
Abl Cytosolic Substrate acetate
|
Abl Cytosolic Substrate acetate(168202-46-8 free base) |
Others
|
|
Abl Cytosolic Substrate acetate is a substrate for Abelson tyrosine kinase (Abl ). |
|
T10800 |
CHMFL-ABL-121
|
|
Bcr-Abl
|
|
CHMFL-ABL-121 is a highly potent inhibitor of type II ABL kinase (IC50s: 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein). |
|
T10799 |
CHMFL-ABL-039
|
|
Bcr-Abl
|
|
CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloid leukemia. |
|
T72958 |
BCR-ABL-IN-7
|
|
Bcr-Abl
|
|
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research. |
|
T10801 |
CHMFL-ABL/KIT-155
|
CHMFL-ABL-KIT-155 |
c-Kit
|
|
CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM). It arrests cell cycle progression and induces apoptosis. |
|
T18595 |
Dasatinib carbaldehyde
|
PROTAC ABL binding moiety 4,BMS-354825 carbaldehyde |
Others
,
Ligands for Target Protein for PROTAC
|
|
Dasatinib carbaldehyde (PROTAC ABL binding moiety 4) is based on Dasatinib which is an ABL inhibitor, binds to the IAP ligand via a linker, and forms SNIPER [1]. |
|
T18690 |
SNIPER(ABL)-039
|
|
Others
|
|
SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of 10 nM. IC50s are 0.54 nM, 10 nM, 12 nM, and 50 nM for ABL, c... |
|
T18686 |
SNIPER(ABL)-019
|
|
Others
|
|
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting a DC50 of 0.3 μM[1]. |
|
T18685 |
SNIPER(ABL)-015
|
|
Others
|
|
SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5 μM [1]. |
|
T39732 |
BCR-ABL-IN-3
|
|
|
|
BCR-ABL-IN-3 is a highly effective and irreversibly binding inhibitor of Bcr-Abl, displaying a remarkable potency with an IC50 value of ≤100 nM for Ba/F3 Bcr-Abl T3151. This compound exhibits significant anti-cancer acti... |
|
T39827 |
C-ABL-IN-1
|
|
|
|
C-ABL-IN-1 is a new and specific inhibitor of the c-Abl protein, which effectively prevents the progression of neurodegeneration observed in Parkinson's disease. |
|
T18684 |
SNIPER(ABL)-013
|
|
Others
|
|
SNIPER(ABL)-013, a compound that links GNF5 (ABL inhibitor) with Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 20 μM[1]. |
|
T18693 |
SNIPER(ABL)-049
|
|
Others
|
|
SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels, demonstrating a DC50 of 100 μM[1]. |
|
T18688 |
SNIPER(ABL)-024
|
|
Others
|
|
SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving a half-maximal degradation concentration (DC50) of... |
|
T18687 |
SNIPER(ABL)-020
|
|
Others
|
|
SNIPER(ABL)-020 is a chemical compound consisting of Dasatinib, an ABL inhibitor, and Bestatin, an IAP ligand, conjugated with a linker. This compound effectively reduces the BCR-ABL protein[1]. |
|
T18691 |
SNIPER(ABL)-044
|
|
Others
|
|
SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving a DC50 value of 10 μM[1]. |
|
T18695 |
SNIPER(ABL)-058
|
|
Others
|
|
SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL protein levels, achieving a half-maximal degradation concentration ... |
|
T18692 |
SNIPER(ABL)-047
|
|
Others
|
|
SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels, achieving a DC50 value of 2 μM[1]. |
|
T34670 |
SNIPER(ABL)-38
|
|
|
|
SNIPER(ABL)-38 is a specific and nongenetic IAP-dependent protein eraser (SNIPER) which acts as a protein degradation inducer of oncogenic BCR-ABL protein. |
|
T18694 |
SNIPER(ABL)-050
|
|
Others
|
|
SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker. This conjugation results in the reduction of BCR-ABL protein[1]. |
|
T18689 |
SNIPER(ABL)-033
|
|
Others
|
|
SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting a DC50 of 0.3 μM[1]. |
|
TP1483 |
Abl Cytosolic Substrate
|
|
|
|
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). |
|
T22067 |
CHMFL-ABL-053
|
|
|
|
CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available BCR-ABL, SRC and p38 kinase inhibitor with IC 50 values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively. CHMFL-ABL-053 is a potentiall... |
|
T18907 |
ABL-001-Amide-PEG3-acid
|
|
Others
|
|
ABL-001-Amide-PEG3-acid, an analogue to ABL-001, primarily serves as a labeled chemical or fluorescent probe. |
|
T10489 |
BCR-ABL-IN-2
|
|
Others
|
|
BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I). |
|
T10488 |
BCR-ABL-IN-1
|
|
Bcr-Abl
|
|
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia. |
|
T63297 |
ABL-L
|
|
|
|
ABL-L is able to induce apoptosis in human laryngeal cancer cells using a p53-dependent pathway. |
|
T5177 |
Asciminib
|
ABL001 |
Bcr-Abl
|
|
Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM). |
|
T61546 |
C-ABL-IN-3
|
|
|
|
c-ABL-IN-3, a highly effective c-Abl inhibitor, exhibits promising potential for studying neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), as well as cancer [1]. The ac... |
|
T62065 |
C-ABL-IN-4
|
|
|
|
c-ABL-IN-4 is a potent inhibitor of c-Abl. |
|
T63332 |
BCR-ABL-IN-5
|
|
|
|
BCR-ABL-IN-5 is a Bcr-Abl (Breakpoint cluster region-Abelson) kinase inhibitor that acts on Bcr-AblWT (IC50: 0.014 μM) and Bcr-AblT3151 (IC50: 0.45 μM) and exhibits some anti-proliferative effects on leukemic cells. effe... |
|
T83711 |
Abl Substrate Peptide TFA
|
|
|
|
Abl substrate peptide, a peptide substrate specifically phosphorylated by the tyrosine kinase Abl rather than c-Src kinase at 20 µM, serves to quantify Abl kinase activity in vitro. This selective phosphorylation undersc... |
|
T82909 |
BCR-ABL-IN-8
|
|
Bcr-Abl
|
|
BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1]. |
|
T63932 |
BCR-ABL-IN-4
|
|
|
|
BCR-ABL-IN-4 is a BCR-ABLL inhibitor that exhibits anticancer activity.BCR-ABL-IN-4 has an inhibitory effect on cancer cell growth and is able to act on K562 cells (IC50: 0.67 nM) and BCR-ABL T315I-transfected Ba/F3 cell... |
|
T63450 |
BCR-ABL-IN-6
|
|
|
|
BCR-ABL-IN-6 (9h) is an imatinib derivative and a selective inhibitor of Bcr-Abl kinase that acts on Bcr-AblWT (IC50: 4.6 nM) and Bcr-AblT3151 (IC50: 277 nM). BCR-ABL-IN-6 (9h) was able to be used in the study of chronic... |
|
T79716 |
C-ABL-IN-5
|
|
Bcr-Abl
|
|
C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability, metabolic stability, and pharmacokinetic profiles. When labeled w... |
|
T61128 |
C-ABL-IN-2
|
|
|
|
C-ABL-IN-2 is a highly effective inhibitor of the c-Abl protein, which plays a significant role in the development of several diseases, including cancer. This compound exhibits promise for investigating neurodegenerative... |
|
T77974 |
PROTAC BCR-ABL Degrader-1
|
|
PROTACs
|
|
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway and demonstrates antiproliferative effects on K562 cells, suggesting its... |
|
T18593 |
GNF5-amido-Me
|
PROTAC ABL binding moiety 2 |
Others
|
|
GNF5-amido-Me, the moiety based on GNF5 (ABL inhibitor),binds through a linker to the IAP ligand forming SNIPER[1]. |
|
T18594 |
HG-7-85-01-Decyclopropane
|
PROTAC ABL binding moiety 3 |
Others
|
|
Decyclopropane, also known as HG-7-85-01, is a chemical compound with ABL inhibitor properties. It binds to the IAP ligand through a linker, resulting in the formation of SNIPER [1]. |
|
T21785 |
AG957
|
|
Bcr-Abl
|
|
Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors[1]. |
|
T0152 |
Bosutinib
|
SKI-606 |
Bcr-Abl
,
Src
,
Autophagy
|
|
Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases. |
|
T18592 |
Imatinib carbaldehyde
|
CGP-57148B carbaldehyde,STI571 carbaldehyde,PROTAC ABL binding moiety 1 |
Others
|
|
Imatinib carbaldehyde (also known as CGP-57148B carbaldehyde) is a compound derived from Imatinib, an inhibitor of the ABL protein. Imatinib carbaldehyde binds to the IAP ligand with the assistance of a linker, resulting... |
|
T3071 |
Olverembatinib
|
GZD 824 |
Bcr-Abl
|
|
Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM). |
|
T8488 |
GMB-475
|
|
Bcr-Abl
|
|
GMB-475 is a BCR-ABL1 tyrosine kinase degrader based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL).resulting in ubiquitinati... |
|
T22553 |
Adaphostin
|
1-Adamantyl 4-((2,5-Dihydroxybenzyl)Amino)Benzoate,NSC 680410 |
Bcr-Abl
|
|
Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM. |
|
T17267 |
XL228
|
|
IGF-1R
,
Bcr-Abl
,
Src
,
Aurora Kinase
|
|
XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively). |
|
T2429 |
Olverembatinib dimesylate
|
GZD824 Dimesylate,HQP1351 |
Bcr-Abl
|
|
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I). |
|
T3063 |
PD173955
|
PD-173955,PD 173955 |
Apoptosis
,
Bcr-Abl
,
Src
|
|
PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC. |
|
T6300 |
Degrasyn
|
WP1130 |
Apoptosis
,
JAK
,
Bcr-Abl
,
DUB
,
Autophagy
|
|
Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without affecting 20S proteasome) and activator of transcri... |
